Retatrutide Cut Weight by 25% in 80 Weeks. The Knee Pain and Sleep Apnea Data Matter More.

On September 29, the two biggest obesity journals published the two biggest obesity trials of the year on the same day. The New England Journal of Medicine ran TRIUMPH-1. The Lancet ran TRIUMPH-2. Both are Phase 3 readouts for retatrutide, Eli Lilly's once-weekly triple hormone agonist, and together they enrolled nearly 3,500 adults treated for 80 weeks.

The headline figure making the rounds is up to 25% body weight loss. That number is real, and we will get to it. But the finding that should reframe how people think about this drug sits further down in the NEJM paper, in two pre-planned subgroup analyses that most coverage has skipped entirely: knee arthritis pain and sleep apnea.

What the two trials actually measured

TRIUMPH-1 enrolled 2,339 adults with obesity and no diabetes. Participants injected retatrutide 4 mg, 9 mg, or 12 mg once weekly, or placebo, for 80 weeks. Mean weight change was -17.6% at 4 mg, -23.7% at 9 mg, and -25.0% at 12 mg, against -3.9% on placebo. Subtract the placebo effect and the top two doses sit roughly 20 to 21 percentage points ahead.

TRIUMPH-2 asked a harder question: what happens in people who already have type 2 diabetes? Across 92 sites in eight countries, 1,152 adults with a BMI of 27 or higher and HbA1c between 6.5% and 10.5% were randomized to the same three doses or placebo. Weight change at week 80 was -11.9%, -16.8%, and -18.8%, against -5.1% on placebo. Glycemic control improved alongside the weight.

If you have been reading GLP-1 trial data for a while, the gap between the two trials will not surprise you. People with type 2 diabetes consistently lose less weight on incretin-class drugs than people without it. The practical translation: roughly 20 to 25% for obesity alone, closer to 12 to 19% when diabetes is in the picture. Same molecule, different floor.

For calibration, the semaglutide STEP 1 trial delivered about 15% at 68 weeks and SURMOUNT-1 put tirzepatide at roughly 21% at 72 weeks. Cross-trial comparisons are unreliable by design, since populations, durations, and estimands differ. Even with that caveat, retatrutide appears to set a new ceiling for pharmacological weight loss.

The endpoints nobody was watching

TRIUMPH-1 was not just a weight trial. Two of its pre-specified primary outcomes were measured in comorbidity subgroups, and this is where the paper gets interesting.

The first subgroup was 574 participants with knee osteoarthritis, scored on the WOMAC pain scale where higher numbers mean worse pain. On the trial's primary hybrid estimand, pain scores fell 3.2, 3.5, and 3.6 points across the three doses, against 1.9 points on placebo. The 9 mg and 12 mg doses beat placebo by 1.6 to 1.8 points on a 10-point scale. On the intention-to-treat analysis the separation holds: -3.4, -3.9, and -4.1 versus -2.5.

The second subgroup was 243 participants with obstructive sleep apnea, measured by the apnea-hypopnea index, which counts breathing interruptions per hour of sleep. The index fell 22.9, 34.3, and 31.7 events per hour across the doses, against 9.9 on placebo. The intention-to-treat figures read -22.8, -34.3, and -32.1 versus -9.6. For someone with moderate apnea, a drop of that size can mean the difference between a CPAP machine and sleeping normally.

These were not post-hoc fishing expeditions. They were registered primary endpoints in pre-defined populations, which puts them in a different evidence class than the usual subgroup throwaway. Why it matters: knee pain and broken sleep are the two things that turn obesity from a number on a scale into a disability. Tirzepatide already holds a sleep apnea indication in the United States. Retatrutide is now laying claim to the same territory, plus joints.

What the safety data says when you read past the weight charts

TRIUMPH-2 published the more granular safety table, and it is worth slowing down for. Diarrhea affected 27 to 34% of participants on retatrutide versus 13% on placebo, and nausea ran 14 to 28% versus 8%. Those numbers track with the rest of the GLP-1 class.

Two signals stand out as less familiar. Hypotension, meaning clinically low blood pressure, appeared in 5 to 6% of the top-dose groups versus under 1% on placebo. Dysesthesia, the tingling or numbness sensation, appeared in 4 to 7% versus 1%. Neither is dangerous on its face. Both are the kind of thing you want to know about before titrating up, especially for anyone already on blood pressure medication.

Discontinuation due to adverse events or death was 12% at 9 mg, 8% at 12 mg, 4% at 4 mg, and 5% on placebo. The fact that the middle dose had more dropouts than the highest dose could be a titration artifact or pure chance in a sample this size. Watch how the full safety publication handles it.

Six participants died across the retatrutide arms, two at 4 mg, three at 9 mg, one at 12 mg, versus one on placebo. Investigators judged every death unrelated to the study drug. At these sample sizes, death counts cannot establish anything statistically. They are reported here because they are the kind of detail that dissolves in press-release retellings, and transparency is the point of reading primary papers.

What this changes, and what it does not

Retatrutide is not FDA-approved. Nothing about your current protocol changes today. These two publications are the evidentiary backbone of Lilly's eventual filing, and the review process will take its own time.

The strategic picture is clearer than it was a week ago. Lilly appears to be building TRIUMPH into a multi-indication program: obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea. If the pain and apnea results hold up in dedicated outcomes trials, the eventual label story shifts from a weight-loss injection to a mobility and sleep treatment that happens to remove a quarter of your body weight. That is a different commercial conversation, and a different clinical one.

The honest gaps remain. The comorbidity findings are subgroup analyses of 574 and 243 people inside a larger trial, with hybrid estimands that partly model treatment failure hypothetically. Both trials are company-funded, as virtually all Phase 3 obesity research is. And 16% of TRIUMPH-2 participants did not complete the study drug, a useful reminder that tolerability at these doses is a real constraint, not a footnote.

The Oria Take

We have covered retatrutide since the Phase 2 data arrived, and our position has been consistent: the efficacy is genuine, the tolerability ceiling is the story, and nothing is real until Phase 3 lands in a peer-reviewed journal. That condition is now met, twice, in the two most cited journals in medicine. The 80-week weight numbers hold up. The comorbidity data is the most exciting development in this drug class since tirzepatide's sleep apnea results, with the usual caveat that subgroups are where promising hypotheses are born, not where they are proven.

If you want one number to remember from TRIUMPH, make it the apnea-hypopnea index. Anyone can market weight loss. A drug that lets people breathe in their sleep is doing something else.

Evidence Grade: A-. Two independently published Phase 3 randomized controlled trials, nearly 3,500 participants, 80 weeks of follow-up, pre-registered endpoints. Downgraded one notch because the most novel findings (knee pain, sleep apnea) come from subgroup analyses with hybrid estimands, all trials are manufacturer-funded, and retatrutide remains unapproved.

Sources

Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026 Sep 29. doi:10.1056/NEJMoa2604169 (TRIUMPH-1, NCT05929066).

Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Sep 29. doi:10.1016/S0140-6736(26)01861-1 (NCT05929079).

Wise J. Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest. BMJ. 2026 Oct 1;395:e101016. doi:10.1136/bmj-2026-101016.

Comparator figures: Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.

Medical Disclaimer

This article is for educational purposes only and is not medical advice. Retatrutide is an investigational compound that has not been approved by the FDA and is not legally available as a prescribed medication. Nothing here should be read as a recommendation to seek out, purchase, or use any unapproved substance. Talk to a licensed physician before making any decision about your health. That is also why Oria exists: the evidence deserves careful reading, and careful reading is a poor substitute for clinical care.